Invokana is an SGLT2 inhibitor that also goes by the names Invokamet, Invokamet XR and canagliflozin. In 2013, the Food and Drug Administration (FDA) approved Invokana to treat adults with type 2 diabetes. More than four years after its approval, it has become clear that Invokana is a defective and unreasonably dangerous drug.
The FDA required Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to include a black box warning for Invokana. A black box warning is the most serious type of warning for an FDA-approved product. The FDA requires a black box warning if evidence exists that a product is hazardous. In this case, the FDA determined that Invokana increases the risk of foot and leg amputations.
Amputations are not the only health risk associated with Invokana. Other complications linked to Invokana include diabetic ketoacidosis, urinary tract infections, thromboembolic events, kidney damage, kidney failure and blood infections. Certain health conditions caused by Invokana may cause permanent injury or death.
You may be eligible to file a lawsuit if you took Invokana and suffered an injury or if you lost a loved one who was taking the drug. Drug manufacturers have a duty to warn patients and physicians of harmful side effects. In addition, drug manufacturers must put their products through rigorous testing. Our law firm is investigating whether Invokana’s manufacturers failed to warn of harmful side effects and if they properly tested their product.
The Philadelphia defective drug attorneys at Eisenberg, Rothweiler, Winkler, Eisenberg & Jeck, P.C. can help you determine whether you or a loved one can file an Invokana lawsuit. It does not cost anything to speak with one of our attorneys. Our law firm has a proven record of recovering millions of dollars in settlements and verdicts for our clients.